Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study Meeting Abstract
| Authors: | Cohen, E.; Uppaluri, R.; Lee, N.; Westra, W.; Haddad, R.; Temam, S.; Le Tourneau, C.; Chernock, R.; Safina, S.; Tao, Y.; Klochikhin, A.; Meirovitz, A.; Brana, I.; Ge, J. Y.; Swaby, R.; Bidadi, B.; Adkins, D. |
| Abstract Title: | Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study |
| Meeting Title: | 2019 ESMO Asia Congress |
| Journal Title: | Annals of Oncology |
| Volume: | 30 |
| Issue: | Suppl. 9 |
| Meeting Dates: | 2019 Nov 22-24 |
| Meeting Location: | Singapore |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-11-01 |
| Start Page: | mdz428.029 |
| Language: | English |
| ACCESSION: | WOS:000503487700305 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdz428.029 |
| Notes: | Meeting Abstract: 316TiP -- Appears on page ix106 of the abstract book -- Source: Wos |
